查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571730

青蒿素聯合治療市場規模、佔有率、趨勢分析報告：按類型、地區、細分市場預測，2024-2030

Artemisinin Combination Therapy Market Size, Share & Trends Analysis Report By Type (Artemether+Lumefantrine, Artesunate+Amodiaquine), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

青蒿素聯合治療市場成長與趨勢：

Grand View Research最新報告顯示，預計2030年全球青蒿素聯合治療市場規模將達10.187億美元，2024年至2030年複合年成長率為8.2%。

ACT 採用率的提高和政府抗擊瘧疾流行的舉措的不斷增加預計將推動市場成長。此外，管道擴張和新產品核准正在推動市場。

目前，世衛組織建議六種治療併發症瘧疾的聯合療法：蒿甲醚-本芴醇（AL）、青蒿琥酯-阿莫地喹（AS-AQ）和青蒿素）。 ACT的優點是療效高、抗藥性細菌發生率低。多年來，青蒿素聯合治療的使用範圍顯著擴大。 2016年，ACT在近80個國家被用作第一線治療。

印度和中國等新興製藥國家不斷增加的研發舉措正在推動 ACT 的採用率。肯亞、烏干達、奈及利亞和剛果等瘧疾流行國家不斷成長的需求可望擴大市場。新抗瘧疾藥的研發管線正在擴大，其中一些藥物最近已推出。這些是推動 ACT 市場發展的一些因素。

世界衛生組織指出，ACT 是治療最嚴重的併發症瘧疾的必要方法，也是最好的治療方法。建議使用 ACT，而不是磺胺多辛-乙胺嘧啶、Chloroquine和單藥青蒿素等其他治療方法。

瘧疾是全世界最具破壞性的疾病之一，每年報告的新病例超過 2 億例。根據 Medicines Malaria Venture (MMV) 的數據，2016 年全球總合445,000 人死於瘧疾。全球瘧疾盛行率持續上升，預計氣候變遷將加速這一趨勢。

青蒿素聯合治療市場報告亮點：

  • 蒿甲醚+本芴醇將佔據市場主導地位，2023年將佔37.1%的佔有率。對蒿甲醚+苯芴醇的需求不斷成長，是因為其在治療併發症瘧疾方面具有卓越的功效和安全性。
  • 北美青蒿素聯合治療市場在2023年佔據最大的市場收益佔有率，為37.7%。需求增加主要是由於輸入性瘧疾病例數量不斷增加以及對有效治療方案的需求。
  • 亞太地區青蒿素聯合治療市場預計在預測期內將以最快的複合年成長率成長。亞太地區對青蒿素聯合治療（ACT）的需求正在增加。
  • 由於瘧疾死灰復燃以及對傳統抗瘧疾藥的抗藥性不斷增加，亞太地區的瘧疾呈現上升趨勢。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章青蒿素聯合治療市場變數、趨勢、範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 青蒿素聯合治療市場分析工具
    • 波特的分析
    • PESTEL分析

第4章青蒿素聯合治療市場：類型估計和趨勢分析

  • 細分儀表板
  • 青蒿素聯合治療市場：類型變異分析，2023 年和 2030 年
  • 蒿甲醚 + 苯芴醇
  • 青蒿琥酯+阿莫地喹
  • 青蒿素+哌喹
  • 青蒿琥酯+甲氟喹
  • 青蒿琥酯+磺胺多辛-乙胺嘧啶
  • 離胺酸咯萘啶
  • 其他

第5章青蒿素聯合治療市場：區域估計與趨勢分析

  • 2023年及2030年青蒿素聯合治療市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第6章 競爭狀況

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Advanced Micro Devices
    • Novartis AG
    • Sanofi SA
    • Cipla Ltd.
    • KPC Pharmaceuticals
    • Fosun Pharmaceutical（Guilin Pharmaceutical）
    • Ajanta Pharma
    • Ipca Laboratories Ltd.
    • Desano Inc.
    • Hovid Berhad
    • Mylan
簡介目錄
Product Code: GVR-2-68038-592-2

Artemisinin Combination Therapy Market Growth & Trends:

The global artemisinin combination therapy market size is expected to reach USD 1,018.7 million by 2030, registering a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising adoption rate of ACTs coupled with growing government initiatives to combat the malaria epidemic is anticipated to stoke the growth of the market. Furthermore, expanding pipeline and new product approvals are driving the market.

Currently, 6 ACTs are recommended by WHO for the treatment of uncomplicated malaria, which are Artemether-Lumefantrine (AL), artesunate-amodiaquine, Artesunate-Mefloquine (AS-AQ), Dihydroartemisinin-Piperaquine (DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine (AS-SP), and Pyronaridine-Artesunate (PR-AS). Some of the benefits provided by ACTs are high efficacy and reduced likelihood of developing resistance. Over the years, access to artemisinin combination therapy has expanded considerably. In 2016, ACTs were used as first-line treatment in almost 80 countries.

Increasing R & D initiatives by pharma-emerging countries such as India and China are revving up the adoption rate of ACTs. Rising demand from malaria endemic countries such as Kenya, Uganda, Nigeria, and Congo is poised to augment the market. Pipeline for new antimalarial drugs is widening and some of them have been introduced recently. These are some of the factors that are propelling the ACT market.

WHO states the necessity for treating uncomplicated malaria, the most serious form of the disease, with ACTs as they are the best treatment available. ACTs are recommended over other treatments including Sulfadoxine-pyrimethamine, chloroquine, and artemisinin monotherapies because parasites have developed resistance to these medicines.

Malaria is one of the most distressing diseases across the globe with more than 200 million new cases reported each year. According to Medicines Malaria Venture (MMV), a total of 445,000 deaths were caused by malaria worldwide in 2016. Malaria epidemic is continuing to increase globally and climate change is projected to fuel the trend.

Artemisinin Combination Therapy Market Report Highlights:

  • Artemether+Lumefantrine dominated the market and accounted for a share of 37.1% in 2023. The rising demand for Artemether+Lumefantrine can be attributed to its superior effectiveness and safety in treating uncomplicated malaria.
  • North America artemisinin combination therapy market held the largest market revenue share of 37.7% in 2023. The increasing demand is primarily due to the rising number of imported malaria cases and the need for effective treatment options.
  • Asia Pacific artemisinin combination therapy market is anticipated to grow at the fastest CAGR over the forecast period. The demand for artemisinin combination therapy (ACT) in the.
  • Asia-Pacific region is increasing due to the resurgence of malaria and the growing resistance to traditional antimalarial drugs.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Artemisinin Combination Therapy Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Artemisinin Combination Therapy Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Artemisinin Combination Therapy Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Artemisinin Combination Therapy Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Artemether+Lumefantrine
    • 4.3.1. Artemether+Lumefantrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Artesunate+Amodiaquine
    • 4.4.1. Artesunate+Amodiaquine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Dihydroartemisinin+Piperaquine
    • 4.5.1. Dihydroartemisinin+Piperaquine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Artesunate+Mefloquine
    • 4.6.1. Artesunate+Mefloquine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Artesunate+Sulfadoxine-Pyrimethamine
    • 4.7.1. Artesunate+Sulfadoxine-Pyrimethamine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Pyronaridine-Artesunate
    • 4.8.1. Pyronaridine-Artesunate Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Other
    • 4.9.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Artemisinin Combination Therapy Market: Regional Estimates & Trend Analysis

  • 5.1. Artemisinin Combination Therapy Market Share, By Region, 2023 & 2030 (USD Million)
  • 5.2. North America
    • 5.2.1. North America Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. U.S.
      • 5.2.2.1. U.S. Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.3. Canada
      • 5.2.3.1. Canada Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.4. Mexico
      • 5.2.4.1. Mexico Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. U.K.
      • 5.3.2.1. U.K. Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Germany
      • 5.3.3.1. Germany Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. France
      • 5.3.4.1. France Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.5. Spain
      • 5.3.5.1. Spain Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.6. Italy
      • 5.3.6.1. Italy Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.7. Sweden
      • 5.3.7.1. Sweden Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.8. Norway
      • 5.3.8.1. Norway Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.9. Denmark
      • 5.3.9.1. Denmark Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. China
      • 5.4.2.1. China Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Japan
      • 5.4.3.1. Japan Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. India
      • 5.4.4.1. India Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. South Korea
      • 5.4.5.1. South Korea Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.6. Australia
      • 5.4.6.1. Australia Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.7. Thailand
      • 5.4.7.1. Thailand Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. Brazil
      • 5.5.2.1. Brazil Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Argentina
      • 5.5.3.1. Argentina Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Middle East and Africa
    • 5.6.1. Middle East and Africa Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.2. Saudi Arabia
      • 5.6.2.1. Saudi Arabia Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. UAE
      • 5.6.3.1. UAE Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.4. South Africa
      • 5.6.4.1. South Africa Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.5. Kuwait
      • 5.6.5.1. Kuwait Artemisinin Combination Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis by Key Market Participants
  • 6.2. Company Categorization
  • 6.3. Company Heat Map Analysis
  • 6.4. Company Profiles
    • 6.4.1. Advanced Micro Devices
      • 6.4.1.1. Participant's Overview
      • 6.4.1.2. Financial Performance
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Recent Developments/ Strategic Initiatives
    • 6.4.2. Novartis AG
      • 6.4.2.1. Participant's Overview
      • 6.4.2.2. Financial Performance
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Recent Developments/ Strategic Initiatives
    • 6.4.3. Sanofi S.A.
      • 6.4.3.1. Participant's Overview
      • 6.4.3.2. Financial Performance
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Recent Developments/ Strategic Initiatives
    • 6.4.4. Cipla Ltd.
      • 6.4.4.1. Participant's Overview
      • 6.4.4.2. Financial Performance
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Recent Developments/ Strategic Initiatives
    • 6.4.5. KPC Pharmaceuticals
      • 6.4.5.1. Participant's Overview
      • 6.4.5.2. Financial Performance
      • 6.4.5.3. Product Benchmarking
      • 6.4.5.4. Recent Developments/ Strategic Initiatives
    • 6.4.6. Fosun Pharmaceutical (Guilin Pharmaceutical)
      • 6.4.6.1. Participant's Overview
      • 6.4.6.2. Financial Performance
      • 6.4.6.3. Product Benchmarking
      • 6.4.6.4. Recent Developments/ Strategic Initiatives
    • 6.4.7. Ajanta Pharma
      • 6.4.7.1. Participant's Overview
      • 6.4.7.2. Financial Performance
      • 6.4.7.3. Product Benchmarking
      • 6.4.7.4. Recent Developments/ Strategic Initiatives
    • 6.4.8. Ipca Laboratories Ltd.
      • 6.4.8.1. Participant's Overview
      • 6.4.8.2. Financial Performance
      • 6.4.8.3. Product Benchmarking
      • 6.4.8.4. Recent Developments/ Strategic Initiatives
    • 6.4.9. Desano Inc.
      • 6.4.9.1. Participant's Overview
      • 6.4.9.2. Financial Performance
      • 6.4.9.3. Product Benchmarking
      • 6.4.9.4. Recent Developments/ Strategic Initiatives
    • 6.4.10. Hovid Berhad
      • 6.4.10.1. Participant's Overview
      • 6.4.10.2. Financial Performance
      • 6.4.10.3. Product Benchmarking
      • 6.4.10.4. Recent Developments/ Strategic Initiatives
    • 6.4.11. Mylan
      • 6.4.11.1. Participant's Overview
      • 6.4.11.2. Financial Performance
      • 6.4.11.3. Product Benchmarking
      • 6.4.11.4. Recent Developments/ Strategic Initiatives